140 related articles for article (PubMed ID: 25271340)
1. Resident rounds part III: plasma cell leukemia with initial cutaneous presentation.
Fabbro SK; Kaffenberger BH
J Drugs Dermatol; 2014 Aug; 13(8):994-5. PubMed ID: 25271340
[No Abstract] [Full Text] [Related]
2. A case of secondary plasma cell leukemia resistant to novel agents, in which stringent complete remission was achieved and maintained for a long period of time after VAD therapy and tandem autologous transplantation.
Sekiguchi Y; Shimada A; Wakabayashi M; Sugimoto K; Tomita S; Izumi H; Nakamura N; Sawada T; Ohta Y; Komatsu N; Noguchi M
Int J Clin Exp Pathol; 2014; 7(9):6313-22. PubMed ID: 25337285
[TBL] [Abstract][Full Text] [Related]
3. Successful treatment with bortezomib-containing regimen of primary plasma cell leukemia: a case report.
Obeidat MB; Al-Swailmeen AM; Arabeat AM; Abukamar AS
Pan Afr Med J; 2020; 36():15. PubMed ID: 32774592
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of bortezomib, lenalidomide and dexamethasone (VRD) in secondary plasma cell leukaemia.
Gozzetti A; Musto P; Defina M; D'Auria F; Papini G; Statuto T; D'Arena G; Bocchia M
Br J Haematol; 2012 May; 157(4):497-8. PubMed ID: 22296516
[No Abstract] [Full Text] [Related]
5. Kappa light chain myeloma with initial cutaneous involvement.
Saka B; Erten N; Oztürk G; Yilmaz C; Dogan O; Buyukbabani N; Besisik SK
Ann Hematol; 2006 Apr; 85(4):272-4. PubMed ID: 16425024
[No Abstract] [Full Text] [Related]
6. Effective combination therapy of bortezomib and dexamethasone for a plasma cell leukemia patient with multiple osteolytic lesions and extramedullary involvement.
Capalbo S; Chiefa A; Delia M; Diomede D; Liso V
Acta Oncol; 2007; 46(2):262-4. PubMed ID: 17453381
[No Abstract] [Full Text] [Related]
7. [Primary plasma cell leukemia (IgD-lambda) with hyperammonemia].
Minauchi K; Fujie T; Matsubara N; Kasahara H; Ogura Y; Tamura M; Yamane Y; Tanaka M; Taneichi K
Nihon Naika Gakkai Zasshi; 2004 Jan; 93(1):139-41. PubMed ID: 14968586
[No Abstract] [Full Text] [Related]
8. Thalidomide-associated hepatitis: a case report.
Fowler R; Imrie K
Am J Hematol; 2001 Apr; 66(4):300-2. PubMed ID: 11279644
[TBL] [Abstract][Full Text] [Related]
9. Primary plasma cell leukemia: a case report of successful responder to a combination chemotherapy of vincristine, doxorubicin and dexamethasone.
Suzuki M; Kawauchi K; Sugiyama H; Yasuyama M; Watanabe H
Acta Haematol; 1989; 82(2):95-7. PubMed ID: 2508402
[TBL] [Abstract][Full Text] [Related]
10. Treatment of plasma cell leukemia with vincristine, liposomal doxorubicin and dexamethasone.
Christou L; Hatzimichael E; Chaidos A; Tsiara S; Bourantas KL
Eur J Haematol; 2001 Jul; 67(1):51-3. PubMed ID: 11553267
[TBL] [Abstract][Full Text] [Related]
11. A comparison of salvage infusional chemotherapy regimens for recurrent/refractory multiple myeloma.
Griffin PT; Ho VQ; Fulp W; Nishihori T; Shain KH; Alsina M; Baz RC
Cancer; 2015 Oct; 121(20):3622-30. PubMed ID: 26149422
[TBL] [Abstract][Full Text] [Related]
12. Long-term disease-free survival in a primary plasma cell leukemia treated by VAD, autologous PBSC transplantation, and IFN-alpha.
Büchler T; Ferra C; Domingo A; Gallardo D; Sarra J; Grańena A
Am J Hematol; 2002 Sep; 71(1):62. PubMed ID: 12221683
[No Abstract] [Full Text] [Related]
13. Salvage therapy with lenalidomide and dexamethasone in relapsed primary plasma cell leukemia.
Musto P; Pietrantuono G; Guariglia R; Villani O; Martorelli MC; D'Auria F; Zonno A; Lerose R
Leuk Res; 2008 Oct; 32(10):1637-8. PubMed ID: 18433866
[No Abstract] [Full Text] [Related]
14. Single-agent venetoclax induces MRD-negative response in relapsed primary plasma cell leukemia with t(11;14).
Jelinek T; Mihalyova J; Kascak M; Duras J; Popkova T; Benkova K; Richterova P; Plonkova H; Zuchnicka J; Broskevicova L; Huvarova L; Cerna L; Growkova K; Simicek M; Havel M; Gumulec J; Navratil M; Koristek Z; Paiva B; Hajek R
Am J Hematol; 2019 Jan; 94(1):E35-E37. PubMed ID: 30370955
[No Abstract] [Full Text] [Related]
15. Combination chemotherapy with bortezomib, cyclophosphamide and dexamethasone may be effective for plasma cell leukemia.
Kim SJ; Kim J; Cho Y; Seo BK; Kim BS
Jpn J Clin Oncol; 2007 May; 37(5):382-4. PubMed ID: 17538191
[TBL] [Abstract][Full Text] [Related]
16. Lenalidomide cutaneous adverse event: a case of Stevens-Johnson syndrome (SJS) in a primary plasma cell leukaemia patient treated with lenalidomide and dexamethasone.
Siniscalchi A; Tendas A; Morino L; Dentamaro T; De Bellis A; Perrotti A; de Fabritiis P; Musto P; Caravita T
Support Care Cancer; 2012 Jul; 20(7):1585-7. PubMed ID: 22562584
[No Abstract] [Full Text] [Related]
17. Primary plasma cell leukemia occuring in the young.
Raj RS; Najeeb S; Aruna R; Pavithran K; Thomas M
Indian J Cancer; 2003; 40(3):116-7. PubMed ID: 14716116
[TBL] [Abstract][Full Text] [Related]
18. Systemic capillary leak syndrome preceding plasma cell leukaemia.
Ghosh K; Madkaikar M; Iyer Y; Pathare A; Jijina F; Mohanty D
Acta Haematol; 2001; 106(3):118-21. PubMed ID: 11713377
[TBL] [Abstract][Full Text] [Related]
19. Treatment of multiple myeloma: 2009 update.
Prescrire Int; 2009 Dec; 18(104):263-6. PubMed ID: 20025098
[TBL] [Abstract][Full Text] [Related]
20. Pegylated liposomal doxorubicin in combination with dexamethasone and bortezomib (VMD) or lenalidomide (RMD) in multiple myeloma pretreated patients.
Buda G; Orciuolo E; Galimberti S; Pelosini M; Petrini M
Ann Hematol; 2011 Sep; 90(9):1115-6. PubMed ID: 21181162
[No Abstract] [Full Text] [Related]
[Next] [New Search]
